Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will
be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain
reduced blood Phe concentrations in PKU subjects.